Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR236553 versus ezetimibe in adults with hypercholesterolemia
NL-OMON36881Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Oct 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alirocumab in hypercholesterolemia (2 arms), sponsored by Sanofi. Primary endpoint: Percent change in LDL cholesterol after 24 weeks. Started Oct 2012; status: active, not recruiting.
02
Drugs
alirocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NL-OMON36881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36881.